TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B Stock
Certificat
DE000CJ5HTN3
| Market Closed - Börse Stuttgart 03:51:41 2024-04-29 am EDT | ||
| 21.01 EUR | +2.24% |
|
| Current month | +1.06% | ||
| 1 month | +1.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 21.01 | +2.24% | 0 |
| 24-04-26 | 20.55 | +0.93% | 0 |
| 24-04-25 | 20.36 | -2.91% | 0 |
| 24-04-24 | 20.97 | +1.16% | 0 |
| 24-04-23 | 20.73 | +2.88% | 0 |
Delayed Quote Börse Stuttgart
Last update April 29, 2024 at 03:51 am EDT
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | CJ5HTN |
| ISIN | DE000CJ5HTN3 |
| Date issued | 2018-11-05 |
| Strike | 109.4 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 1.12 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.78 € |
|---|---|
| Lowest since issue | 1.02 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
884.8
DKK
Average target price
904.2
DKK
Spread / Average Target
+2.19%
- Stock Market
- Certificates
- Certificat
